###begin article-title 0
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 219 225 <span type="species:ncbi:9606">humans</span>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
Type I diabetes (TID) is an autoimmune disease resulting from destruction of the insulin-producing beta-cells by autoreactive T cells. Studies have shown that polymorphisms of chemokine CXCL12 gene are linked to TID in humans. In non-obese diabetic (NOD) mice, which are predisposed to develop the disease, reduction of CXCL12 level leads to significant delays in the onset of diabetes. Despite these initial observations, however, how CXCL12 affects development of TID has not been fully investigated.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
We found that the level of CXCL12 transcript is significantly elevated in the bone marrow of NOD mice as compared to Balb/c and C57BL/6 mice. Correspondingly, naive T cells, regulatory T cells and hematopoietic stem cells (HSC) accumulate in the bone marrow of NOD mice. Treatment of NOD mice with AMD3100, an antagonist for CXCL12's receptor CXCR4, mobilizes T cells and HSC from the bone marrow to the periphery, concomitantly inhibits insulitis and delays the onset of diabetes.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 229 235 <span type="species:ncbi:9606">humans</span>
These results suggest that the elevated CXCL12 expression promotes TID in NOD mice by altering T cell and hematopoietic stem cell trafficking. The findings highlight the potential usefulness of AMD3100 to treat or prevent TID in humans.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 349 350 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 351 352 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 435 437 432 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 591 592 588 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 593 594 590 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 716 717 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 718 719 715 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
###xml 334 339 <span type="species:ncbi:9606">human</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
Type I diabetes (TID) is an autoimmune disease, resulting from destruction of the insulin-producing beta-cells in the islets of Langerhans by autoreactive T cells. The non-obese diabetic (NOD) mice, which are predisposed to develop the disease, have served as a model for studying the mechanism, pathogenesis and interventions of the human disease [1,2]. In NOD mice, a unique major histocompatibility complex (MHC) class II allele (IAg7) in combination with a defect in the programmed cell death pathway is thought to permit autoreactive T cells to escape negative selection in the thymus [3-5]. In the periphery, additional defects in peripheral tolerance mechanisms enable activation of the autoreactive T cells [6-8], leading to the disease development.
###end p 9
###begin p 10
###xml 586 587 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 956 958 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 959 961 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1153 1155 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1156 1158 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 900 906 <span type="species:ncbi:9606">humans</span>
###xml 971 975 <span type="species:ncbi:10090">mice</span>
Besides development and activation of autoreactive T cells, factors that regulate T cell trafficking likely contribute to the disease development because destruction of beta-cells requires infiltration of autoreactive T cells into the islets. Chemokines are a group of low molecular weight proteins and regulate cell trafficking by binding to specific G-protein-coupled seven-span transmembrane receptors on target cells. For example, CXCL12, also known as stromal cell derived factor-1 (SDF-1), and its receptor CXCR4 play a critical role in regulating hematopoietic cell trafficking [9]. It is required for fetal liver-derived hematopoietic stem cells (HSC) to colonize the bone marrow during embrogenesis and retention/homing of these cells in the bone marrow in the adult. It also regulates trafficking of many other cell types that express CXCR4, including lymphocytes and cancer stem cells. In humans, polymorphisms in CXCL12 gene are linked to TID [10-12]. In NOD mice, the onset of diabetes is significantly delayed by reducing the level of CXCL12 either by antibody-mediated neutralization or G-CSF-induced suppression of CXCL12 transcription [13-16]. Despite these initial observations, however, how chemokine CXCL12 affects development of TID has not been fully investigated.
###end p 10
###begin p 11
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 467 471 <span type="species:ncbi:10090">mice</span>
In this report, we show that expression of chemokine CXCL12 is elevated in the bone marrow of NOD mice, resulting in accumulation of both T cells and HSC in the bone marrow. Treatment of NOD mice with CXCR4 antagonist AMD3100 [17] mobilizes T cells from the bone marrow to peripheral lymphoid tissues, and significantly delays the onset of insulitis and diabetes. Our findings suggest that the elevated CXCL12 expression in the bone marrow likely promotes TID in NOD mice by altering T cell trafficking and stem cell mobilization.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Naive T cells accumulate in the bone marrow of NOD mice
###end title 13
###begin p 14
###xml 162 164 162 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 390 392 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 500 501 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 577 578 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 655 657 647 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 682 683 672 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 703 705 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 807 809 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 902 904 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 1027 1029 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
Compared to age-matched Balb/c or C57BL/6 mice, prediabetic NOD mice (15-16 week-old and no detectable urine glucose) had a significantly higher percentage of CD4+ T cells (~3-fold) in the bone marrow (Figure 1A and data not shown). The increase was even more pronounced in diabetic NOD mice (23 week-old, urine glucose >/= 500 mg/dl), reaching up to 15-fold of that in Balb/c mice (Figure 1A). Correspondingly, the number of CD4 T cells in the bone marrow of prediabetic NOD mice (0.86 +/- 0.38 x 106) was 3 times higher than that in the Balb/c bone marrow (0.29 +/- 0.16 x 106), although both bone marrows had similar number of cells (41.6 +/- 11.1 x 106 versus 46.4 +/- 13.3 x 106, p < 0.09) (Figure 1B). In diabetic NOD mice, the percentages of CD4 T cells in the bone marrow increased with age (Figure 1C) and the increase was correlated with a decrease of CD4 T cell number in the spleen (Figure 1D). A similar increase in the percentage and number of CD8 T cells was also observed in the bone marrow of NOD mice (Figure 1B and data not shown).
###end p 14
###begin p 15
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Accumulation of na&#239;ve T cells in the bone marrow of NOD mice</bold>
###xml 451 452 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 455 457 449 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 949 951 943 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1114 1116 1108 1110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1750 1751 1744 1745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1754 1756 1748 1750 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 846 850 <span type="species:ncbi:10090">mice</span>
###xml 938 942 <span type="species:ncbi:10090">mice</span>
###xml 1103 1107 <span type="species:ncbi:10090">mice</span>
###xml 1185 1189 <span type="species:ncbi:10090">mice</span>
###xml 1214 1219 <span type="species:ncbi:10090">mouse</span>
###xml 1331 1335 <span type="species:ncbi:10090">mice</span>
###xml 1472 1476 <span type="species:ncbi:10090">mice</span>
###xml 1522 1526 <span type="species:ncbi:10090">mice</span>
Accumulation of naive T cells in the bone marrow of NOD mice. A. Frequency of CD4 T cells in the bone marrow of Balb/c, prediabetic and diabetic NOD mice. Cells from bone marrow (BM), spleen (SP) and pooled lymph nodes (LN, including cervical, mediastinal, auxiliary, brachial, mesenteric, and inguinal nodes) were stained for CD4, CD8, TCRbeta, and PI. CD4 versus TCRbeta profiles are shown for live cells. The numbers indicate the percentages of CD4+TCR+ cells in the gated regions. p < 0.001 comparing percentages of CD4 T cells in the bone marrow between Balb/c and NOD mice. B. The average number of CD4 (open bar) and CD8 (solid bar) T cells in the BM, LN and SP of Balb/c (n = 22), prediabetic (n = 19) and diabetic (n = 16) NOD mice. p < 0.01 comparing CD4 or CD8 T cells in the bone marrow between Balb/c and prediabetic or diabetic NOD mice. C. Increase of percentages of CD4 T cells with age in the bone marrow of diabetic NOD mice. The r2 value is 0.76. D. Inverse correlation between percentage of CD4 T cells in the bone marrow and CD4 T cell number in the spleen of the same diabetic NOD mice. The r2 value is -0.69. Data presented in C and D are from the same group of mice. One dot represents one mouse. E. Comparison of percentages of CD4 T cells in the bone marrow of 4-5 week old BLAB/c (n = 6) and NOD (n = 8) mice. p < 0.001. F. Comparison of percentages of CD4 T cells in the bone marrow of 6-9 week old Balb/c (n = 5), EA16 (n = 3) and NOD (n = 8) mice. p < 0.001 comparing Balb/c to NOD (or EA16) mice. G. Phenotype of bone marrow T cells. Bone marrow cells were stained for TCR, CD4, CD25 plus CD45RB, or for TCR, CD4, CD44 and CD45RB. Representative plots from at least four independent experiments are shown, gating on CD4+TCR+ cells.
###end p 15
###begin p 16
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 534 536 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 651 653 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1F</xref>
###xml 738 740 734 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 746 748 742 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 752 754 748 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 776 778 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1G</xref>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 528 532 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
###xml 838 842 <span type="species:ncbi:10090">mice</span>
###xml 945 949 <span type="species:ncbi:10090">mice</span>
To investigate the role of inflammation or hyperglycemia in the T cell accumulation in the bone marrow of NOD mice, we used 4-5 week-old NOD mice, in which insulitis (inflammation) was minimal. As shown in Figure 1E, the percentage of CD4 T cells in the bone marrow was still significantly higher (1.2 +/- 0.3%) than in age-matched Balb/c mice (0.2 +/- 0.03%). Furthermore, in EA16 mice, which do not develop diabetes because the transgenic expression of an I-E molecule confers almost complete protection from insulitis of NOD mice [18], the percentage of CD4 T cells in the bone marrow was significantly increased as compared to Balb/c mice (Figure 1F). In addition, most CD4 T cells in the bone marrow of prediabetic NOD mice were CD44loCD45RBhiCD25- naive T cells (Figure 1G). The proportion of the naive T cells increased as the NOD mice became diabetic. Together, these results show that naive T cells accumulate in the bone marrow of NOD mice.
###end p 16
###begin title 17
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Increased homing leads to T cell accumulation in the bone marrow of NOD mice
###end title 17
###begin p 18
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 423 426 423 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi </sup>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
To determine if T cell accumulation in the bone marrow of NOD mice was due to proliferation, T cells in the bone marrow were stained for cycling marker Ki67. No significant difference in the percentages of Ki67+proliferating CD4 T cells was detected in the bone marrow of prediabetic NOD mice and age-matched Balb/c mice (Figure 2A). As in Balb/c mice, the proliferating CD4 T cells in the bone marrow of NOD mice were CD44hi effector or memory T cells.
###end p 18
###begin p 19
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">T cell accumulation in the bone marrow of NOD mice is due to homing</bold>
###xml 332 333 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 336 338 336 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 379 381 379 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 472 476 <span type="species:ncbi:10090">mice</span>
###xml 518 522 <span type="species:ncbi:10090">mice</span>
###xml 873 877 <span type="species:ncbi:10090">mice</span>
T cell accumulation in the bone marrow of NOD mice is due to homing. A. Comparison of steady-state level of CD4 T cell proliferation in the bone marrow of 15-16 week-old Balb/c and prediabetic NOD mice. Bone marrow cells were stained for TCR, CD4, CD44 and Ki67. Representative Ki67 versus CD44 expression profiles are shown for TCR+CD4+ cells. The numbers are percentage of Ki67+ cells. B. Comparison of T cell homing to the bone marrow and lymph nodes in Balb/c and NOD mice. CFSE-labeled T cells from Balb/c or NOD mice were injected intravenously into both Balb/c and NOD recipients (12-16 week-old) and analyzed 2 hours following the transfer. Homing index is calculated by dividing percentage of CFSE-positive donor CD4 T cells in the bone marrow or lymph nodes by that in the spleen of the same recipient. Mean +/- SD of homing index of CD4 T cells in at least four mice per group is shown. *p < 0.01.
###end p 19
###begin p 20
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 886 887 886 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
###xml 690 694 <span type="species:ncbi:10090">mice</span>
###xml 1004 1008 <span type="species:ncbi:10090">mice</span>
###xml 1230 1234 <span type="species:ncbi:10090">mice</span>
To investigate the role of recruitment in T cell accumulation in the bone marrow, total T cells were purified from NOD and Balb/c mice, labeled with CFSE, and transferred into both NOD and Balb/c mice. Distribution of CFSE-positive donor CD4 T cells in the recipients was assayed 2 hours following the transfer. No significant difference was detected in T cell distribution in the lymph nodes between Balb/c and NOD mice when either NOD or Balb/c T cells were transferred (Figure 2B right panel), demonstrating that T cells from Balb/c and NOD mice have equivalent motility. However, significantly more transferred Balb/c and NOD T cells were detected in the bone marrow of NOD than Balb/c mice (Figure 2B left panel). Forty-eight hours after the transfer, the difference between T cell distribution in the bone marrow of NOD and Balb/c recipients was even greater (see Additional file 1). Therefore, enhanced recruitment likely contributes to the accumulation of naive T cells in the bone marrow of NOD mice. Because the enhanced recruitment is restricted to the bone marrow and independent of the source of the donor T cells, factors that mediate the preferential homing of naive T cells likely reside in the bone marrow of NOD mice.
###end p 20
###begin title 21
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Elevated CXCL12 expression promotes T cell recruitment to the bone marrow of NOD mice
###end title 21
###begin p 22
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 867 869 867 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3E</xref>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 166 171 <span type="species:ncbi:10090">Mouse</span>
###xml 292 296 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
###xml 660 664 <span type="species:ncbi:10090">mice</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
###xml 830 834 <span type="species:ncbi:10090">mice</span>
###xml 1076 1080 <span type="species:ncbi:10090">mice</span>
To identify chemokines that mediate the observed preferential T cell homing, we compared chemokine transcription in the bone marrow between NOD and Balb/c mice using Mouse Chemokines & Receptors Microarrays. Only chemokine CXCL12 and CCL19 transcripts were elevated in the bone marrow of NOD mice as compared to Balb/c mice (Figure 3A). Quantitative RT-PCR analysis showed that the CXCL12 transcript was 3-5 fold higher in the bone marrow of NOD than Balb/c mice (Figure 3B), whereas the difference in the level of CCL19 transcript was not confirmed. Consistently, the level of CXCL12 transcript was significantly higher in the bone marrow of 4-5 week-old NOD mice and EA16 mice than their respective age-matched controls (Figure 3C and 3D). In addition, majority of CD4 T cells in the spleen, lymph nodes, and bone marrow of NOD mice that expressed CXCR4 were CD45RB+ naive T cells (Figure 3E), consistent with their accumulation in the bone marrow. Although only a few percentages of CD4 T cells stained positive for surface CXCR4, all CD4 T cells from both NOD and C57BL/6 mice were positive for intracellular staining of CXCR4 (data not shown).
###end p 22
###begin p 23
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Elevated CXCL12 expression correlates with T cell accumulation in the bone marrow of NOD mice</bold>
###xml 1148 1149 1148 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1152 1154 1152 1154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 722 726 <span type="species:ncbi:10090">mice</span>
###xml 746 750 <span type="species:ncbi:10090">mice</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
###xml 976 980 <span type="species:ncbi:10090">mice</span>
###xml 1037 1041 <span type="species:ncbi:10090">mice</span>
Elevated CXCL12 expression correlates with T cell accumulation in the bone marrow of NOD mice. A. Analysis of chemokine expression in the bone marrow. RNA was isolated from bone marrow of Balb/c (n = 5) and prediabetic NOD (n = 6) mice, pooled, labeled and used as a probe to hybridize with GEArray chemokine array filters. Representative chemiluminescent images from the hybridization are shown. 1, CCL19; 2, CXCL12. B. Quantitation of CXCL12 and CCL19 transcripts by RT-PCR. The same RNA as in A was used in real-time RT-PCR analysis for CXCL12, CCL19 and GAPDH. The relative transcript levels of CXCL12 and CCL19 to GAPDH are shown. C. Comparison of CXCL12 transcript levels in the bone marrow between 4-5 week-old NOD mice (n = 8) and Balb/c mice (n = 6). D. Comparison of CXCL12 transcript levels in the bone marrow among 6-9 week-old Balb/c (n = 5), EA16 (n = 3) and NOD (n = 8) mice. E. CXCR4 expression by CD4 T cells in different organs of Balb/c and prediabetic NOD mice. Cells from BM, LN and SP of Balb/c and prediabetic NOD mice were stained for TCR, CD4, CD45RB and CXCR4. Representative CXCR4 versus CD45RB profiles are shown for TCR+CD4+ cells. The numbers indicate percentages of cells in the gated areas. * p < 0.05.
###end p 23
###begin p 24
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 666 669 666 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi </sup>
###xml 673 675 673 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 731 735 <span type="species:ncbi:10090">mice</span>
###xml 957 961 <span type="species:ncbi:10090">mice</span>
AMD3100 is a low molecular weight antagonist of CXCR4 [17]. If interaction of CXCL12 with CXCR4 is critical for the observed T cell accumulation, treatment of NOD mice with AMD3100 should inhibit T cell accumulation in the bone marrow. Thus, prediabetic NOD mice were given AMD3100 (5 mg/kg) daily for 8 days and the distribution and phenotype of T cells in their bone marrow were assayed. AMD3100 treatment significantly reduced the proportion of both CD4 and CD8 T cells in the bone marrow of the prediabetic NOD mice as compared to prediabetic NOD mice that were given PBS (Figure 4A). In particular, the proportion of CD4 T cells with the naive phenotype (CD45RBhi CD44lo) was preferentially reduced in the AMD3100 treated NOD mice (Figure 4B). Together with CXCL12's known function in regulating T cell migration [19], these results demonstrate that the elevated CXCL12 expression results in the accumulation of naive T cells in the bone marrow of NOD mice.
###end p 24
###begin p 25
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AMD3100 inhibits naive T cell accumulation in the bone marrow of NOD mice</bold>
###xml 453 454 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 457 459 455 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 621 624 617 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi </sup>
###xml 628 631 624 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo </sup>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
###xml 514 518 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 721 725 <span type="species:ncbi:10090">mice</span>
AMD3100 inhibits naive T cell accumulation in the bone marrow of NOD mice. Prediabetic NOD mice (15-16 weeks of age) were treated with PBS or AMD3100 (AMD) daily for 8 days. Two hr after the last AMD3100 injection, mice were analyzed by flow cytometry. A, Comparison of percentage of CD4 and CD8 T cells (mean +/- SD) in the bone marrow of AMD3100 (n = 4) and PBS (n = 6) treated NOD mice. * p < 0.05. B, Comparison of CD44 versus CD45RB profiles of TCR+CD4+ cells from AMD3100 (n = 4) and PBS (n = 6) treated NOD mice. The numbers indicate percentages of cells in the gated areas. The percentages (mean +/- SE) of CD45RBhi CD44lo naive T cells are 47.3 +/- 10.9 for PBS-treated mice and 24.8 +/- 3.2 for AMD3100-treated mice (p < 0.01).
###end p 25
###begin title 26
Elevated CXCL12 expression promotes recruitment/retention of regulatory T cells (Tregs) and hematopoietic stem cells in the bone marrow
###end title 26
###begin p 27
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 490 491 490 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 494 496 494 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 1018 1020 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1218 1220 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 393 397 <span type="species:ncbi:10090">mice</span>
###xml 565 569 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
###xml 675 679 <span type="species:ncbi:10090">mice</span>
###xml 702 706 <span type="species:ncbi:10090">mice</span>
###xml 915 919 <span type="species:ncbi:10090">mice</span>
###xml 1205 1209 <span type="species:ncbi:10090">mice</span>
The elevated CXCL12 expression is expected to promote recruitment or retention of other cell types/subsets that express CXCR4 in the bone marrow of NOD mice. Although no significant difference in percentage or number of NKT cells, dendritic cells or B cells was detected in the bone marrow between NOD and Balb/c mice (data not shown) nor any change in distribution of these cell types in NOD mice following AMD3100 treatment (see Additional file 2 and data not shown), the numbers of Foxp3+CD4+ Tregs were consistently higher in the bone marrow of prediabetic NOD mice than Balb/c mice (Figure 5A). A lower percentage of CD4 T cells that are Tregs in the bone marrow of NOD mice as compared to Balb/c mice likely reflects the greater accumulation of naive CD4 T cells than Tregs in the NOD bone marrow. To unequivocally determine the involvement of CXCL12-CXCR4 interaction in regulating Treg trafficking, we used mice in which CXCR4 expression was specifically inactivated in T cells via Cre-mediated recombination [20]. In the absence of CXCR4, the numbers of Treg in the bone marrow was decreased significantly whereas the number of Treg in the spleen was increased as compared to littermate wildtype mice (Figure 5B). Thus, Treg trafficking into the bone marrow is partly regulated by CXCL12.
###end p 27
###begin p 28
###xml 0 117 0 117 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The elevated CXCL12 expression promotes recruitment/retention of Treg and hematopoietic stem cells in the bone marrow</bold>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 176 178 176 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 373 374 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 379 380 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 383 385 383 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 421 423 421 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 459 461 459 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 587 592 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcr4</italic>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f/f </italic>
###xml 592 596 592 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>f/f </italic></sup>
###xml 629 634 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcr4</italic>
###xml 636 638 636 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f </italic>
###xml 634 638 634 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>f </italic></sup>
###xml 729 730 729 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 733 734 733 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 738 739 738 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 744 746 744 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 875 876 875 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 880 881 880 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 886 887 886 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
###xml 997 1001 <span type="species:ncbi:10090">mice</span>
The elevated CXCL12 expression promotes recruitment/retention of Treg and hematopoietic stem cells in the bone marrow. A. Comparison of the percentages and numbers of Foxp3+CD4+ Tregs in the bone marrow between age-matched Balb/c (n = 7) and prediabetic NOD (n = 20) mice (15 weeks of age). Bone marrow cells were assayed for TCR, CD4 and Foxp3. Tregs are identified as TCR+Foxp3+CD4+ cells. The percentage value of Foxp3+ cells is expressed as percent of CD4+ T cells. B. Effect of CXCR4 deletion on Treg distribution in the spleen and bone marrow. Cells from spleen and bone marrow of Cxcr4f/f Lck-Cre (KO) mice and littermate Cxcr4+/f Lck-Cre (WT) (8 weeks of age) were assayed for TCR, CD4, CD25 and Foxp3. The numbers of TCR+CD4+CD25+Foxp3+ cells are compared in the spleen and bone marrow from 3 mice per group. C. Comparison of numbers of hematopoietic stem cells (Lin-Sca1+c-Kit+, LSK) among age-matched Balb/c (n = 5), prediabetic NOD (n = 5) and AMD3100-treated (8 days) prediabetic NOD mice (n = 4). *p < 0.05.
###end p 28
###begin p 29
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 120 121 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 131 133 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 232 236 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
CXCL12 plays a critical role in retention of HSC in the bone marrow of adult mice [9,21]. As expected, the number of Lin-Sca1+c-Kit+ HSC was significantly higher in the bone marrow of prediabetic NOD mice than in age-matched Balb/c mice (Figure 5C). Following AMD3100 treatment for 8 days, the number of HSC in the bone marrow of NOD mice was significantly reduced.
###end p 29
###begin title 30
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Interference of CXCR4 function delays the development of diabetes in NOD mice
###end title 30
###begin p 31
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 553 555 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 560 562 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 805 807 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
###xml 1403 1405 1399 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 428 432 <span type="species:ncbi:10090">mice</span>
###xml 586 590 <span type="species:ncbi:10090">mice</span>
###xml 677 681 <span type="species:ncbi:10090">mice</span>
###xml 851 855 <span type="species:ncbi:10090">mice</span>
###xml 984 988 <span type="species:ncbi:10090">mice</span>
###xml 1077 1081 <span type="species:ncbi:10090">mice</span>
###xml 1204 1208 <span type="species:ncbi:10090">mice</span>
###xml 1282 1286 <span type="species:ncbi:10090">mice</span>
###xml 1371 1375 <span type="species:ncbi:10090">mice</span>
###xml 1449 1453 <span type="species:ncbi:10090">mice</span>
To determine the relationship between CXCL12-mediated dysregulation of T cell and stem cell trafficking and development of diabetes, we treated NOD mice with AMD3100 and monitored progression of the disease. As shown in Figure 6A, prediabetic NOD mice had significantly more insulin-expressing islets than diabetic NOD mice (26.7 +/- 5.2 per section versus 15.8 +/- 9.4 per section, p < 0.05). Among age-matched prediabetic NOD mice, AMD3100 treatment (daily for 8 days) significantly reduced lymphocyte infiltration into the islets (insulitis) (Figure 6A and 6B). When prediabetic NOD mice (15-16 weeks of age) were given AMD3100 or PBS daily for three weeks, PBS-treated NOD mice rapidly developed diabetes between 17 and 20 weeks of age as indicated by glucose levels in the urine (>500 mg/dl) (Figure 6C). In contrast, none of the AMD3100-treated mice developed glycosuria disease during the same period. However, two weeks after AMD3100 treatment was terminated, AMD3100-treated mice began to develop diabetes and the incidence reached the same level (70%) as PBS-treated mice by 26 weeks of age. To test whether continuous AMD3100 treatment can inhibit the development of diabetes, prediabetic NOD mice (15 weeks of age) were given AMD3100 daily for 14 weeks. PBS-treated NOD mice started to show evidence of diabetes at 16 weeks of age and by 29 weeks of age, all mice developed diabetes (Figure 6D). In contrast, none of the AMD3100-treated mice developed the disease during the same period. These results show that AMD3100 treatment inhibits leukocyte infiltration in the islets (insulitis) and continuous treatment delays development of overt diabetes.
###end p 31
###begin p 32
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AMD3100 treatment inhibits leukocyte infiltration and development of diabetes in NOD mice</bold>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 512 517 <span type="species:ncbi:10090">mouse</span>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
###xml 872 876 <span type="species:ncbi:10090">mice</span>
###xml 905 909 <span type="species:ncbi:10090">Mice</span>
AMD3100 treatment inhibits leukocyte infiltration and development of diabetes in NOD mice. A. Immunohistological staining of pancreatic sections of NOD mice. The pancreas of prediabetic, diabetic NOD mice or prediabetic NOD mice that have been given AMD3100 for 8 days were fixed and embedded. Parallel tissue sections were stained with haematoxylin and eosin (H&E, top panel), anti-glucagon (middle panel) or anti-insulin (bottom panel) antibodies. Note lymphocyte infiltration in the islets of prediabetic NOD mouse without AMD3100 treatment. B. Percentage of insulitis in pancreatic sections of 15 week-old prediabetic NOD mice that were given daily with PBS (n = 8) or AMD3100 (n = 6) for 8 days. *p < 0.01. C and D. Comparison of diabetes incidence in NOD mice that were given AMD3100 or PBS for 3 weeks (C) or 14 weeks (D), starting at 15-16 weeks of age. Number of mice in each group (n) is shown. Mice are scored as diabetic when glucose level in the urine reaches 500 mg/dl. p < 0.01.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 807 811 <span type="species:ncbi:10090">mice</span>
###xml 915 919 <span type="species:ncbi:10090">mice</span>
###xml 1091 1095 <span type="species:ncbi:10090">mice</span>
We show here that among all chemokines examined the level of CXCL12 transcript, which is tightly correlated with the protein level [14], is significantly elevated in the bone marrow of NOD mice as compared to Balb/c mice. CXCL12 specifically stimulates chemotaxis of cells that express CXCR4 [20,22,23]. The elevated CXCL12 levels are therefore expected to have a significant effect on recruitment and retention of CXCR4-expressing cells in the bone marrow of NOD mice. Based on analyses of young, prediabetic, diabetic NOD mice and EA16 mice, the phenotype of CXCR4-expressing T cells, the effect of AMD3100 treatment, and direct recruitment assay, our studies unequivocally demonstrate that the elevated CXCL12 expression results in recruitment and accumulation of naive T cells in the bone marrow of NOD mice. Because there is no difference in the proportion of T cells that express CXCR4 between NOD and Balb/c mice, and because Balb/c T cells are also preferentially recruited to the NOD bone marrow, the observed recruitment and accumulation of naive T cells in the bone marrow of NOD mice appears to be due solely to the elevated CXCL12 expression. In addition, our results show that the elevated CXCL12 expression also leads to the accumulation/retention of Tregs and HSC in the bone marrow.
###end p 34
###begin p 35
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 873 875 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1332 1334 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1486 1488 1486 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1489 1491 1489 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1780 1782 1780 1782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1783 1785 1783 1785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1821 1823 1821 1823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1901 1902 1901 1902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 330 334 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 796 802 <span type="species:ncbi:9606">humans</span>
###xml 929 947 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 1110 1118 <span type="species:ncbi:9606">patients</span>
###xml 1216 1220 <span type="species:ncbi:10090">mice</span>
###xml 1480 1484 <span type="species:ncbi:10090">mice</span>
###xml 1694 1698 <span type="species:ncbi:10090">mice</span>
###xml 1726 1729 <span type="species:ncbi:31658">CFA</span>
###xml 1875 1879 <span type="species:ncbi:10090">mice</span>
###xml 1943 1947 <span type="species:ncbi:10090">mice</span>
###xml 2153 2157 <span type="species:ncbi:10090">mice</span>
###xml 2173 2179 <span type="species:ncbi:9606">humans</span>
What is the relationship between the elevated CXCL12 expression in the bone marrow and development of diabetes in NOD mice? The elevated CXCL12 expression is unlikely a consequence of inflammation or hyperglycemia associated with insulitis or diabetes in NOD mice because CXCL12 transcript was detected in the bone marrow of EA16 mice and young (4-5 week old) NOD mice. More likely, NOD mice are predisposed to express elevated CXCL12 in the bone marrow. Conversely, because EA16 mice do not develop diabetes despite the elevated CXCL12 expression and accumulation of T cells in the bone marrow, the elevated CXCL12 expression alone is insufficient to initiate diabetes in the absence of autoreactive T cells. Nevertheless, the elevated CXCL12 expression likely promotes diabetes development. In humans, polymorphisms in CXCL12 gene are linked to susceptibility to TID [10-12]. Using allele-specific transcript quantification in Epstein-Barr virus-transformed lymphoblastoid cell lines, one study reported evidence that polymorphisms have a cis-acting effect on CXCL12 transcription [24]. However, whether TID patients with specific CXCL12 polymorphisms have elevated CXCL12 expression has not been reported. In NOD mice, neutralization of CXCL12 by administration of antibody suppresses insulitis and delays the onset of diabetes [15]. Similarly, administration of G-CSF, a cytokine known to induce suppression of CXCL12 transcription, also reduces insulitis and diabetes in NOD mice [15,16]. Consistent with these previous observations, we found that the elevated CXCL12 expression and its consequent effect on T cell trafficking are positively correlated with the disease progression in NOD mice. Complete Freund adjuvant (CFA), which is known to inhibit diabetes development [25,26], also inhibits CXCL12 expression [27] and T cell accumulation in the bone marrow of NOD mice (see Additional file 3). Finally, treatment of prediabetic NOD mice with AMD3100 abolishes T cell accumulation in the bone marrow and simultaneously inhibits disease development. Together, these findings strongly suggest that CXCL12 promotes development of diabetes in NOD mice and perhaps in humans.
###end p 35
###begin p 36
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1033 1035 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1036 1038 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1213 1215 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1304 1306 1304 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 473 477 <span type="species:ncbi:10090">mice</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 1408 1412 <span type="species:ncbi:10090">mice</span>
###xml 1424 1428 <span type="species:ncbi:10090">mice</span>
Our findings also suggest potential mechanisms by which the elevated CXCL12 expression promotes disease progression in NOD mice. We found that the elevated CXCL12 expression leads to homing of naive T cells to the bone marrow. A recent study showed that diabetogenic T cells also preferentially home to the bone marrow of NOD mice [28], perhaps as a result of the elevated CXCL12 expression shown here. It is possible that accumulation of T cells in the bone marrow of NOD mice might lead to lymphopenia in the peripheral lymphoid organs and homeostatic proliferation and differentiation of autoreactive T cells [29-32], which in turn promotes diabetes development. It is also possible that elevated CXCL12 expression may promote disease progression in NOD mice through its effect on trafficking of autoreactive T cells, especially into islets. Studies have shown that CXCL12-CXCR4 interaction is required for recruitment of autoreactive T cells to rheumatoid arthritis synovium and the inflamed joint of collagen-induced arthritis [33,34]. In a virus-induced TID model, blockade of CXCL10 (IP-10) prevents diabetes development by impeding expansion of autoreactive T cells and their migration into the pancreas [35]. We showed that inhibition of CXCR4 by AMD3100 significantly reduced insulitis (Figure 5B). Although we did not detect any difference in CXCL12 expression in pancreas between prediabetic NOD mice and BALB/c mice (data not shown), dysregulation of lymphocyte trafficking is likely a significant contributing factor to the development of TID in NOD.
###end p 36
###begin p 37
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 318 320 318 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 655 656 655 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 1046 1047 1046 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 277 281 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
###xml 1119 1123 <span type="species:ncbi:10090">mice</span>
The elevated CXCL12 expression may promote disease progression in NOD mice through its effect on Treg trafficking, which is partly regulated by CXCL12-CXCR4 interaction. A large body of evidence suggests that Tregs play a critical role in suppressing autoimmunity [36]. In NOD mice, the frequency and function of Foxp3+ Tregs were reported to decrease with age [37]. We show that more Tregs were present in the bone marrow of NOD mice than age-matched BALB/C mice. Following AMD3100 treatment of NOD mice, the number of Tregs was significantly decreased in the bone marrow whereas the number was significantly increased in the spleen (see Additional file 4). However, because the number of Tregs in the bone marrow is only about one tenth of that in the spleen, Treg mobilization from the bone marrow alone cannot account for the significant increase in Treg numbers in the spleen. Regardless where the splenic Tregs come from, because a threshold ratio of Tregs to autoreactive T cells is important for Treg suppression of autoreactive T cells [6,38], sequestering Tregs in the bone marrow or some other organs in NOD mice may tip the balance in favor of autoreactive T cells.
###end p 37
###begin p 38
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 616 619 <span type="species:ncbi:31658">CFA</span>
###xml 766 770 <span type="species:ncbi:10090">mice</span>
The elevated CXCL12 expression also leads to retention of hematopoietic stem cells in the bone marrow of NOD mice. Because bone marrow-derived stem cells initiate pancreatic regeneration [39], it is possible that sequestering HSC and possibly other stem/progenitor cells in the bone marrow might contribute to disease progression in NOD mice by limiting their availability for islet regeneration. In support of this notion, systemic administration of CXCL12 ameliorates diabetes [40], perhaps partly by mobilizing HSC from the bone marrow to the periphery. The same mechanism may partly explain the effectiveness of CFA plus adoptive transfer of splenocytes, which contain a significant number of HSC and probably other progenitor cells [41], in curing diabetic NOD mice through regeneration of islets [42-45].
###end p 38
###begin p 39
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
###xml 661 665 <span type="species:ncbi:10090">mice</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
###xml 927 931 <span type="species:ncbi:10090">mice</span>
###xml 1067 1071 <span type="species:ncbi:10090">mice</span>
###xml 1321 1329 <span type="species:ncbi:9606">patients</span>
AMD3100 was originally developed to treat HIV infection through its antagonism of the CXCR4, a co-receptor for the virus [17]. Currently, it is being developed as an agent to mobilize HSC from bone marrow to peripheral blood for transplantation of stem cells in patients with non-Hodgkin's lymphoma or multiple myeloma [46]. We found that AMD3100 treatment of prediabetic NOD mice significantly delays insulitis and the onset of diabetes. In contrast, a recent study reported that AMD3100 treatment promotes diabetes development in a model where diabetes was induced by adoptive transfer of splenocytes from female NOD mice into sublethally irradiated male NOD mice [47]. In the transfer model, transferred T cells undergo homeostatic proliferation and acquire effector functions [30-32]. Irradiation of the recipient mice also introduces additional factors and processes which are not active in the non-irradiated prediabetic mice. Thus, the disease induction mechanisms in the transfer model could be significantly different from those in un-manipulated female NOD mice. Although the precise mechanism underlying the discrepancy between the two studies has yet to be determined, our finding provides a basis for further exploring the use of AMD3100 to prevent and/or treat TID and possibly other autoimmune diseases in patients with elevated CXCL12 or CXCR4 expression.
###end p 39
###begin title 40
Conclusion
###end title 40
###begin p 41
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 227 233 <span type="species:ncbi:9606">humans</span>
Elevated CXCL12 expression in the bone marrow of NOD mice likely promotes development of TID by altering T cell and hematopoietic stem cell trafficking. The findings suggest the possibility of preventing and/or treating TID in humans by modulating either the expression or function of CXCL12 and CXCR4.
###end p 41
###begin title 42
Methods
###end title 42
###begin title 43
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 43
###begin p 44
###xml 573 578 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcr4</italic>
###xml 578 579 578 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 580 582 580 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f </italic>
###xml 578 582 578 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>f</italic>/<italic>f </italic></sup>
###xml 610 615 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcr4</italic>
###xml 617 619 617 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f </italic>
###xml 615 619 615 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>f </italic></sup>
###xml 699 704 699 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcr4</italic>
###xml 706 708 706 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f </italic>
###xml 704 708 704 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/<italic>f </italic></sup>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 222 226 <span type="species:ncbi:10090">Mice</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 590 594 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 726 730 <span type="species:ncbi:10090">mice</span>
###xml 821 825 <span type="species:ncbi:10090">mice</span>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
NOD mice from Taconic Farms were bred in our facilities. Female NOD mice were used in all studies and monitored for diabetes by checking the urine glucose level at least two times per week, starting around 12 week of age. Mice were considered diabetic when urinary glucose level reached 500 mg/dl, as measured with Diastix (Bayer Diagnostics). In our facility, approximately 95% of untreated NOD female mice became diabetic by 7-months of age. Balb/c mice were purchased from the Jackson Laboratory. EA16NOD mice were a gift from Drs. Diane Mathis and Christopher Benoist. Cxcr4f/f Lck-Cre mice and littermate Cxcr4+/f Lck-Cre were on the mixed 129/C57BL/6 background and were generated by breeding Cxcr4+/f Lck-Cre mice. All mice were kept under specific pathogen free facilities. For AMD3100 treatment, prediabetic NOD mice were given AMD3100 (5 mg/kg) subcutaneously daily for the indicated length of time. For analysis of T cell distribution, the mice were sacrificed after 2 hour of last AMD3100 injection. All animal studies are approved by the institutional Committees on Animal Care.
###end p 44
###begin title 45
Antibodies and flow cytometry
###end title 45
###begin p 46
###xml 394 396 393 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Single-cell suspensions were prepared from the spleen, lymph nodes and bone marrow. All staining antibodies were purchased from BDbioscience, except anti-Foxp3, lineage markers (Lin), and c-Kit and Sca-1, which were from E-bioscience, Stem Cell Technologies, and Biolegend, respectively. Cells were stained in the presence of 2.5 mug/ml anti-FcR antibody in PBS containing 0.1% BSA and 0.1% NaN3 and analyzed on a FACScaliber or a LSR II or a FACSAria, collecting 10,000 to 1,000,000 live cells per sample. Analyses were carried out with Flowjo software. For analysis of LSK cells, 10% of total cells with low level of lineage marker expression were gated for further analysis of Sca-1 versus c-kit expression profile. Intracellular staining of Foxp3 and Ki67 was performed according to the manufacturer's instruction.
###end p 46
###begin title 47
Immunohistochemistry
###end title 47
###begin p 48
###xml 206 216 <span type="species:ncbi:10141">guinea pig</span>
The pancreata were fixed in 10% formalin, embedded in paraffin, and sectioned. Paraffin-embedded tissue sections were stained with haematoxylin and eosin, and parallel sections were stained with polyclonal guinea pig anti-insulin (Zymed) or anti-glucagon antibodies (Linco Research Inc.), followed by incubation with ABC systems Kit (Vector laboratories). For destructive insulitis (loss of insulin staining), insulin-stained sections of pancreata were matched to serial sections stained for glucagon. Insulitis is defined as presence of infiltrating lymphocytes in islets regardless whether they stained positive for insulin or not.
###end p 48
###begin title 49
Chemokine gene expression
###end title 49
###begin p 50
###xml 248 252 248 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 252 257 <span type="species:ncbi:10090">Mouse</span>
RNA was isolated from bone marrow using Trizol (Invitrogen), reverse transcribed using the Ampho-Labeling kit (Superarray, Frederick, MD), and the cDNA was labeled with biotin-16-dUTP (Roche). Cytokine expression was assessed using an Oligo GEArray(R) Mouse Chemokines & Receptors Microarray (Superarray, Frederick, MD). Real-time PCR for CXCL12, CCL19, and GAPDH transcripts was performed with the probes and master mixture kit from Applied Biosystems.
###end p 50
###begin title 51
Homing of T cells
###end title 51
###begin p 52
###xml 375 377 374 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 488 490 487 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 540 542 539 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 861 863 860 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 895 897 894 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 511 515 <span type="species:ncbi:10090">mice</span>
###xml 805 809 <span type="species:ncbi:10090">mice</span>
T cells were purified from lymph nodes and spleens from 12-16 week old NOD and Balb/c mice by negative depletion using a MACS and staining with biotinylated antibodies specific for CD11b, CD11c and B200 and subsequently with streptavidin-microbeads. The purified T cells (> 95% purity) were labeled with 1.5 muM CFSE, washed and then suspended in HBSS solution. 20 or 50 x 106 CFSE-labeled cells were transferred into the NOD and Balb/c mice. After 2 hr (for mice transferred with 50 x 106 cells) or 48 hr (for mice transferred with 20 x 106 cells) recipients were sacrificed, and the frequency of transferred CD4 T cells was determined in the bone marrow, lymph nodes and spleen by flow cytometry assaying for CFSE and CD4. To correct for differences in the input cell numbers among individual recipient mice, the homing index (HI) was calculated: HI = [% CFSE+ CD4 T cells in BM or LN]/[% CFSE+ CD4 T cells in spleen].
###end p 52
###begin title 53
Statistics
###end title 53
###begin p 54
Statistical analysis for significance was done with either a two-tailed Student's t-test or a Kaplan-Meier product limit estimation. Error bars shown in all figures are one standard deviation.
###end p 54
###begin title 55
List of abbreviations
###end title 55
###begin p 56
###xml 114 117 <span type="species:ncbi:31658">CFA</span>
CXCL12: chemokine (C-X-C motif) ligand 12; SDF-1: stromal cell-derived factor-1; CXCR4: CXC chemokine receptor 4; CFA: complete Freund's adjuvant; G-CSF: granulocyte colony-stimulating factor; HSC: hematopoietic stem cells; TID: type I diabetes.
###end p 56
###begin title 57
Authors' contributions
###end title 57
###begin p 58
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcr4</italic>
###xml 207 208 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 209 211 209 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f </italic>
###xml 207 211 207 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>f</italic>/<italic>f </italic></sup>
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cxcr4</italic>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 270 272 270 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f </italic>
###xml 268 272 268 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>f</italic>/<italic>f </italic></sup>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
QL conceived of the study, designed most of the experiments, collected data, analyzed and interpreted data, performed statistical analysis, and drafted the manuscript; YN collected and analyzed data on Cxcr4f/f Lck-Cre mice; YZ analyzed and interpreted data from Cxcr4f/f Lck-Cre mice; JC coordinated the study, participated in the experimental design, analyzed and interpreted data, and drafted the manuscript. All authors read and approved the final manuscript.
###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin title 60
Additional file 1
###end title 60
###begin p 61
Figure s1
###end p 61
###begin p 62
Click here for file
###end p 62
###begin title 63
Additional file 2
###end title 63
###begin p 64
Figure s2
###end p 64
###begin p 65
Click here for file
###end p 65
###begin title 66
Additional file 3
###end title 66
###begin p 67
Figure s3
###end p 67
###begin p 68
Click here for file
###end p 68
###begin title 69
Additional file 4
###end title 69
###begin p 70
Figure s4
###end p 70
###begin p 71
Click here for file
###end p 71
###begin title 72
Acknowledgements
###end title 72
###begin p 73
###xml 58 62 <span type="species:ncbi:10090">mice</span>
We thank Drs. Diane Mathis and Chritophe Benoist for EA16 mice and helpful suggestions on this study, Dr. H. N. Eisen and members of the Chen lab for advice, comments and review of the manuscript, Dr. Sharon Gedekel, Dr. Stephan Kissler, Dr. Cheng Cheng Zhang, Alicia Caron and Ron Bronson for technical helps. AMD3100 (JM-2987) was obtained through the NIH AIDS Research and Reference Reagent program. The CD1d tetramer loaded with PBS57 was obtained through the NIH Tetramer Facility, NIAID, NIH. The work was supported partly by NIH grants (AI50631, AI40146 and AI69208 to JC), the Sandler Program in Asthma Research (to YZ), and a core grant to the MIT Center for Cancer Research (CA140451 to Tyler Jacks).
###end p 73
###begin article-title 74
Checkpoints in the progression of autoimmune disease: lessons from diabetes models
###end article-title 74
###begin article-title 75
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
The NOD mouse: a model of immune dysregulation
###end article-title 75
###begin article-title 76
###xml 37 41 <span type="species:ncbi:10090">mice</span>
A defect in central tolerance in NOD mice
###end article-title 76
###begin article-title 77
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Defective central tolerance induction in NOD mice: genomics and genetics
###end article-title 77
###begin article-title 78
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD
###end article-title 78
###begin article-title 79
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes
###end article-title 79
###begin article-title 80
Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes
###end article-title 80
###begin article-title 81
###xml 109 113 <span type="species:ncbi:10090">mice</span>
The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice
###end article-title 81
###begin article-title 82
Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis
###end article-title 82
###begin article-title 83
A common stromal cell-derived factor-1 chemokine gene variant is associated with the early onset of type 1 diabetes
###end article-title 83
###begin article-title 84
Stromal-cell derived factor-1 chemokine gene variant is associated with type 1 diabetes age at onset in Japanese population
###end article-title 84
###begin article-title 85
Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications
###end article-title 85
###begin article-title 86
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4
###end article-title 86
###begin article-title 87
G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow
###end article-title 87
###begin article-title 88
###xml 102 106 <span type="species:ncbi:10090">mice</span>
Role of stromal-cell derived factor-1 in the development of autoimmune diseases in non-obese diabetic mice
###end article-title 88
###begin article-title 89
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+)CD25(+) regulatory T-cells
###end article-title 89
###begin article-title 90
The bicyclam AMD3100 story
###end article-title 90
###begin article-title 91
###xml 61 76 <span type="species:ncbi:10090">transgenic mice</span>
Correcting an immune-response deficiency by creating Ea gene transgenic mice
###end article-title 91
###begin article-title 92
Lymphocyte responses to chemokines
###end article-title 92
###begin article-title 93
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development
###end article-title 93
###begin article-title 94
Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine singaling in bone marrow stromal cell niches
###end article-title 94
###begin article-title 95
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract
###end article-title 95
###begin article-title 96
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1
###end article-title 96
###begin article-title 97
Allele-specific transcript quantification detects haplotypic variation in the levels of the SDF-1 transcripts
###end article-title 97
###begin article-title 98
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Prevention of type I diabetes in NOD mice by adjuvant immunotherapy
###end article-title 98
###begin article-title 99
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice
###end article-title 99
###begin article-title 100
Inflammation Controls B Lymphopoiesis by Regulating Chemokine CXCL12 Expression
###end article-title 100
###begin article-title 101
Bone marrow is a preferential homing site for autoreactive T-cells in type 1 diabetes
###end article-title 101
###begin article-title 102
Homeostatic expansion of T cells during immune insufficiency generates autoimmunity
###end article-title 102
###begin article-title 103
Maintaining the norm: T-cell homeostasis
###end article-title 103
###begin article-title 104
Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory cells
###end article-title 104
###begin article-title 105
Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation
###end article-title 105
###begin article-title 106
###xml 171 175 <span type="species:ncbi:10090">mice</span>
AMD a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice
###end article-title 106
###begin article-title 107
Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis
###end article-title 107
###begin article-title 108
Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease
###end article-title 108
###begin article-title 109
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self
###end article-title 109
###begin article-title 110
Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes
###end article-title 110
###begin article-title 111
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells
###end article-title 111
###begin article-title 112
Bone marrow-derived stem cells initiate pancreatic regeneration
###end article-title 112
###begin article-title 113
###xml 68 72 <span type="species:ncbi:10090">mice</span>
Stromal cell-derived factor-1 (SDF-1/CXCL12) attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt
###end article-title 113
###begin article-title 114
Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments
###end article-title 114
###begin article-title 115
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Islet regeneration during the reversal of autoimmune diabetes in NOD mice
###end article-title 115
###begin article-title 116
###xml 31 37 <span type="species:ncbi:10090">murine</span>
Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution
###end article-title 116
###begin article-title 117
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration
###end article-title 117
###begin article-title 118
Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells
###end article-title 118
###begin article-title 119
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma
###end article-title 119
###begin article-title 120
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
The CXCR4/CXCL12 (SDF-1) signaling pathway protects non-obese diabetic mouse from autoimmune diabetes
###end article-title 120

